fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-07-21
Company: Novagali Pharma (France)
Investors: Several existing shareholders (Edmond de Rothschild Investment Partners, IDInvest Partners, Auriga Partners, FCJE, Siparex/Sigefi, 123 Venture and Bernard Chauvin) have made purchase commitments totalling over € 9 m.
Amount: €22 million
Planned use: Novagali Pharma will use these funds to complete the clinical development of Cyclokat® and of Vekacia® without a partner, with a view to launching these products by 2013 and to continue the development of Catioprost® and Cortiject®.
Other: Novagali Pharma has raised €22 million in its initial public offering on Alternext by NYSE Euronext Paris. Shares have been proposed at €3.4.